Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.
Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma
by MM360 Staff | Jun 11, 2021 | Myeloma News | 0 comments